Biogen Appoints Adam Keeney as Head of Corporate Development
Biogen has announced the appointment of Adam Keeney, Ph.D., as Executive Vice President and Head of Corporate Development, effective April 17, 2023. Dr. Keeney is set to join the Executive Committee and will report to Christopher A. Viehbacher, the company's President and CEO. With over 20 years in biopharmaceutical strategy and business development, Dr. Keeney previously served as CEO of NodThera and held significant roles at Sanofi and Johnson & Johnson. His appointment comes as Biogen aims for sustainable growth and strategic external collaborations.
- Appointment of Dr. Adam Keeney expected to enhance strategic growth opportunities.
- Dr. Keeney's extensive experience in biopharmaceuticals may lead to value-creating partnerships.
- Concerns regarding continuity and experience gaps following management changes.
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.
“We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable experience in biopharmaceutical strategy and business development with a solid track record of value-creating deals throughout his career,” said Mr. Viehbacher. “As we are working to put Biogen on a sustainable growth trajectory, Adam will focus on advancing the company’s strategy and pursuing external collaborations and other growth opportunities.”
Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, most recently as the Chief Executive Officer of NodThera, a clinical stage biotech company advancing a portfolio of NLRP3 inflammasome inhibitors for the treatment of a broad range of inflammatory diseases.
Prior to joining NodThera, Dr. Keeney was at Sanofi where he had responsibility for all of Sanofi Genzyme’s business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. Previously, Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at H. Lundbeck A/S.
Dr. Keeney holds a Ph.D. in Neuropharmacology from the University of Nottingham, UK and a Bachelor of Science in Neuropsychology from the University of Leeds, UK.
About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including statements relating to our business activities; our strategy and plans and the potential of our commercial business and pipeline programs; capital allocation and investment strategy. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
This news release speaks only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT: Biogen Jack Cox + 1 210 544 7920 public.affairs@biogen.com | INVESTOR CONTACT: Biogen Mike Hencke +1 781 464 2442 IR@biogen.com |
FAQ
What is the significance of Adam Keeney's appointment as Executive Vice President at Biogen?
When did Adam Keeney start his position at Biogen?
What roles did Adam Keeney hold before joining Biogen?
How might Adam Keeney's experience benefit Biogen?
What is Biogen's strategy following the appointment of the new executive?
